Compass Therapeutics【CMPX】銘柄情報

Compass Therapeutics Inc (CMPX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

2.02

( -5.16% )

買値

1.58

売値

2.49

出来高

3,144,399

2.03 日の範囲 2.12

1.50 52 週間の範囲 6.88

時価総額

363.778M

前日終値

2.13

始値

2.10

時刻

2.0196

最終取引時間

財務取引量

US$ 6,522,448

VWAP

2.0743

平均取引量 (3 か月)

US$ 0

発行済株式数

180,087,915

配当利回り

PER

-6

1 株当たり利益 (EPS)

-0.4

歳入

純利益

-68.17M

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (... Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.compasstherapeutics.com

本社

Boston, United States

設立

2026

Compass Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker CMPX. The last closing price for Compass Therapeutics was US$2.13. Over the last year, Compass Therapeutics shares have traded in a share price range of US$ 1.50 to US$ 6.88.

Compass Therapeutics currently has 180,087,915 shares in issue. The market capitalisation of Compass Therapeutics is US$363.78 million. Compass Therapeutics has a price to earnings ratio (PE ratio) of -6.00.

全体の流れ

ブルリッシュ

ネットプレミアム

145k

Calls / Puts

100.00%

買い / 売り

0.00%

OTM / ITM

0.00%

Sweeps比率

0.00%

Compass Therapeutics to Participate in Upcoming June Investor Events

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.41	-16.8724279835	2.43	2.47	2	4981021	2.19663519	CS
4	0.22	12.2222222222	1.8	2.47	1.75	5157106	2.04196571	CS
12	-3.25	-61.669829222	5.27	6.845	1.5	7969101	2.47767697	CS
26	-3.57	-63.8640429338	5.59	6.88	1.5	4875155	3.24063126	CS
52	-0.16	-7.33944954128	2.18	6.88	1.5	3156870	3.36390933	CS
156	-0.91	-31.0580204778	2.93	6.88	0.765	1499968	2.97472489	CS
260	-2.08	-50.7317073171	4.1	6.88	0.765	1014028	2.99129743	CS